Zacks: Brokerages Expect Hologic, Inc. (NASDAQ:HOLX) Will Announce Quarterly Sales of $1.28 Billion

Analysts expect Hologic, Inc. (NASDAQ:HOLXGet Rating) to post $1.28 billion in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Hologic’s earnings. The highest sales estimate is $1.28 billion and the lowest is $1.27 billion. Hologic posted sales of $1.54 billion during the same quarter last year, which suggests a negative year-over-year growth rate of 16.9%. The business is scheduled to report its next quarterly earnings report after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Hologic will report full-year sales of $4.39 billion for the current financial year, with estimates ranging from $3.88 billion to $4.55 billion. For the next fiscal year, analysts anticipate that the business will report sales of $3.94 billion, with estimates ranging from $3.90 billion to $4.00 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Hologic.

Hologic (NASDAQ:HOLXGet Rating) last announced its earnings results on Wednesday, February 2nd. The medical equipment provider reported $2.17 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.97. The firm had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.21 billion. Hologic had a net margin of 31.23% and a return on equity of 48.46%. The company’s revenue for the quarter was down 8.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.86 EPS.

A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company cut their target price on shares of Hologic from $95.00 to $90.00 and set an “overweight” rating on the stock in a research note on Thursday, February 3rd. Raymond James dropped their price objective on shares of Hologic from $88.00 to $84.00 and set an “outperform” rating on the stock in a research note on Thursday, February 3rd. began coverage on shares of Hologic in a research note on Thursday, March 31st. They set a “buy” rating on the stock. Finally, Morgan Stanley decreased their target price on shares of Hologic from $76.00 to $75.00 and set an “equal weight” rating for the company in a report on Thursday, February 3rd. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from, Hologic presently has a consensus rating of “Buy” and an average price target of $81.78.

In other Hologic news, insider Sean S. Daugherty sold 2,179 shares of the stock in a transaction dated Thursday, February 24th. The shares were sold at an average price of $71.14, for a total transaction of $155,014.06. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 1.54% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in HOLX. Fieldpoint Private Securities LLC raised its position in Hologic by 61.4% during the 1st quarter. Fieldpoint Private Securities LLC now owns 334 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 127 shares during the last quarter. CVA Family Office LLC purchased a new stake in Hologic in the 4th quarter worth $30,000. Dark Forest Capital Management LP purchased a new stake in Hologic in the 3rd quarter worth $40,000. Quent Capital LLC purchased a new stake in Hologic in the 4th quarter worth $51,000. Finally, Rosenberg Matthew Hamilton purchased a new stake in Hologic in the 1st quarter worth $55,000. Institutional investors own 93.12% of the company’s stock.

Shares of HOLX opened at $73.93 on Friday. The firm’s 50-day moving average price is $73.94 and its 200-day moving average price is $73.24. The firm has a market capitalization of $18.48 billion, a price-to-earnings ratio of 11.12, a PEG ratio of 1.17 and a beta of 1.12. The company has a current ratio of 2.74, a quick ratio of 2.34 and a debt-to-equity ratio of 0.63. Hologic has a 1-year low of $60.10 and a 1-year high of $81.04.

Hologic Company Profile (Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

Recommended Stories

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with's FREE daily email newsletter.